Home / Stocks / AMGN

Amgen (AMGN, Biotechnology) Stock Valuation & Fair Value Trading above fair value

Amgen (AMGN, Biotechnology) trades at a blended P/E of 19.2, about 35% above its historical normal valuation, with a forward growth estimate of 5.6% and a PEG of 3.44. Analysts' one-year estimates have been hit 82% of the time.

DATA AS OF 2026-08-21
Blended P/E
19.2
Normal P/E
14.2
PEG
3.44
Fwd growth
5.6%
Div yield
2.3%
RSI (14)
74.3
Overbought

The Street vs SeerForecast

Wall Street's mean price target for AMGN is $383.66 across 29 analysts, 12.7% below the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: trading above fair value. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from fairly valued (2026-06-03) to trading above fair value (2026-08-21).

Price and rating by weekClose moved +22.8 percent from 2026-06-03 to 2026-08-17, with 1 rating change over 21 recorded weeks.2026-06-03: Fairly valued, close 338.22 (recalculated)2026-06-10: Fairly valued, close 337.73 (recalculated)2026-06-14: Fairly valued, close 355.20 (recalculated)2026-06-16: Fairly valued, close 347.84 (recalculated)2026-06-21: Fairly valued, close 337.60 (recalculated)2026-07-02: Fairly valued, close 374.15 (recalculated)2026-07-06: Fairly valued, close 366.44 (recalculated)2026-07-09: Fairly valued, close 363.62 (recalculated)2026-07-12: Fairly valued, close 363.39 (recalculated)2026-07-13: Fairly valued, close 360.45 (recalculated)2026-07-14: Fairly valued, close 355.25 (recalculated)2026-07-20: Fairly valued, close 364.17 (recalculated)2026-07-22: Fairly valued, close 366.05 (recalculated)2026-07-25: Fairly valued, close 376.04 (recalculated)2026-07-27: Fairly valued, close 376.26 (recalculated)2026-07-31: Trading above fair value, close 385.16 (recalculated)2026-08-03: Trading above fair value, close 385.162026-08-07: Trading above fair value, close 410.95 (recalculated)2026-08-10: Trading above fair value, close 410.952026-08-14: Trading above fair value, close 415.21 (recalculated)2026-08-17: Trading above fair value, close 415.213384152026-06-032026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-03P/E 0.0—Fairly valued
2026-06-10P/E 15.8+11%Fairly valued
2026-06-14P/E 15.8+11%Fairly valued
2026-06-16P/E 15.8+11%Fairly valued
2026-06-21P/E 15.8+11%Fairly valued
2026-07-02P/E 16.3+15%Fairly valued
2026-07-06P/E 16.9+19%Fairly valued
2026-07-09P/E 16.9+19%Fairly valued
2026-07-12P/E 16.4+16%Fairly valued
2026-07-13P/E 16.4+16%Fairly valued
2026-07-14P/E 16.4+16%Fairly valued
2026-07-20P/E 16.5+17%Fairly valued
2026-07-22P/E 16.5+17%Fairly valued
2026-07-25P/E 17.0+20%Fairly valued
2026-07-27P/E 17.0+20%Fairly valued
2026-07-31P/E 17.5+23%Trading above fair value
2026-08-03P/E 17.4+22%Trading above fair value
2026-08-07P/E 18.0+27%Trading above fair value
2026-08-10P/E 18.3+29%Trading above fair value
2026-08-14P/E 18.6+31%Trading above fair value
2026-08-17P/E 18.4+30%Trading above fair value
2026-08-21P/E 19.2+35%Trading above fair value ← now

Frequently asked questions

Is Amgen stock overvalued?

At a blended P/E of 19.2 versus its historical normal P/E of 14.2, Amgen trades about 35% above its typical valuation, with a PEG of 3.44 on 5.6% forward growth. tickerseer currently rates it trading above fair value.

What is Amgen's fair value and PEG?

Amgen trades at a blended P/E of 19.2 against a historical normal P/E of 14.2, a PEG of 3.44, and a forward growth estimate of 5.6%.

Has tickerseer's rating of Amgen changed?

tickerseer's rating moved from fairly valued (2026-06-03) to trading above fair value (2026-08-21).

What is the analyst price target for Amgen?

The mean Wall Street price target for Amgen is $383.66 across 29 analysts, 12.7% below the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track AMGN free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.